Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DWJ1386 vs Co-administration of DWC20155 and DWC20156 in Healthy Subjects
NCT03016494Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DWC20155 and DWC20156 in gastritis and Peptic ulcer disease (PUD) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area under the plasma concentration versus time curve. Status: unknown.
02
Drugs
DWC20155DWC20156
03
Conditions
gastritisPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT03016494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03016494.